Holen Sie sich die Stockscreener-App
5.68
4.54%
-0.27
Handel nachbörslich:
5.65
-0.03
-0.53%
Schlusskurs vom Vortag:
$5.95
Offen:
$5.62
24-Stunden-Volumen:
17.90M
Relative Volume:
0.66
Marktkapitalisierung:
$2.27B
Einnahmen:
$64.60M
Nettoeinkommen (Verlust:
$-377.75M
KGV:
-3.6645
EPS:
-1.55
Netto-Cashflow:
$-335.64M
1W Leistung:
-12.48%
1M Leistung:
+10.72%
6M Leistung:
-21.55%
1J Leistung:
-22.62%
1-Tages-Spanne:
$5.575
$5.82
1-Wochen-Bereich:
$5.575
$6.685
52-Wochen-Spanne:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Firmenname
Recursion Pharmaceuticals Inc
Sektor
Branche
Telefon
(385) 269-0203
Adresse
41S RIO GRANDE STREET, SALT LAKE CITY
Vergleichen Sie RXRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
5.68 | 2.58B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Eingeleitet | Needham | Buy |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-04 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Eingeleitet | Berenberg | Buy |
| 2021-05-11 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Eingeleitet | JP Morgan | Neutral |
| 2021-05-11 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
Should I hold or sell Recursion Pharmaceuticals Inc. stock in 2025Daily Trading Alerts For Every Investor - jammulinksnews.com
What are the latest earnings results for Recursion Pharmaceuticals Inc.Market Forecast Alerts Backed By Experts - jammulinksnews.com
When is Recursion Pharmaceuticals Inc. stock expected to show significant growthFinancial News Outlook For 2025 - jammulinksnews.com
What catalysts could drive Recursion Pharmaceuticals Inc. stock higher in 2025Financial News Data Feed With Proven Results - jammulinksnews.com
What is the risk reward ratio of investing in Recursion Pharmaceuticals Inc. stockSwing Trade Growth Plan With High Returns - jammulinksnews.com
How does Recursion Pharmaceuticals Inc. generate profit in a changing economyBreakout Stocks Ideas For 2025 - jammulinksnews.com
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Drug Discovery Platforms Market Size Expected to Reach USD 635.45 Million by 2034 - GlobeNewswire Inc.
The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades. - AOL.com
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today - Yahoo Finance
Recursion's Q2 2025 Earnings: A TechBio Powerhouse Poised for Breakthroughs and Synergy-Driven Growth - AInvest
Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th - FinancialContent
Short Covering May Lift Recursion Pharmaceuticals Inc. in Near TermWeekly Growth Stock Entry Point Alerts Highlighted - metal.it
Why Recursion Pharmaceuticals Stock Got Mashed on Monday - AOL.com
Why Recursion Pharmaceuticals (RXRX) Soared On Friday - MSN
Recursion Pharmaceuticals Inc. Approaches Psychological Resistance LevelBreakout Entry Signal Confirmation Tool Used - metal.it
Tempus AI (TEM) vs. Recursion (RXRX): Which AI Biotech Stock Is Better? - 24/7 Wall St.
What institutional investors are buying Recursion Pharmaceuticals Inc. stockMaximize profits with strategic stock selection - jammulinksnews.com
What is the dividend policy of Recursion Pharmaceuticals Inc. stockMaximize gains with timely market signals - jammulinksnews.com
How volatile is Recursion Pharmaceuticals Inc. stock compared to the marketUnlock powerful stock screening techniques - jammulinksnews.com
Palantir, Nvidia & Tempus AI: The Future of Medicine in 2025 - AInvest
Big Pharma's Disruption: AI-Powered Palantir, Tempus, and Recursion Change the Game - AInvest
Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills - Benzinga
RXRX Stock Surges: What Awaits Next? - timothysykes.com
Recursion Pharmaceuticals Inc. Stock Analysis and ForecastAccelerated financial growth - PrintWeekIndia
Recursion Pharmaceuticals call volume above normal and directionally bullish - TipRanks
How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma - Benzinga
RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now? - Yahoo Finance
Is Recursion Pharmaceuticals Inc. a good long term investmentAccelerated capital growth - PrintWeekIndia
What drives Recursion Pharmaceuticals Inc. stock priceStrongest growth potential - Autocar Professional
How high can Recursion Pharmaceuticals Inc. stock price go in 2025Rapid return acceleration - jammulinksnews.com
Recursion Pharmaceuticals (RXRX) Soars 5.8%: Is Further Upside Left in the Stock? - MSN
What analysts say about Recursion Pharmaceuticals Inc. stockSignificant capital appreciation - PrintWeekIndia
RXRX September 5th Options Begin Trading - Nasdaq
Recursion Pharmaceuticals Experiences 10.7% Stock Price Surge Amid Strong Investor Interest - AInvest
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note - MSN
Recursion Pharmaceuticals (RXRX) Jumps 9.6% Ahead of Q2 Earnings - MSN
Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses? - The Globe and Mail
Recursion Pharmaceuticals Trading Volume Drops 52.75% to $23.7 Million, Ranks 464th in Market - AInvest
Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia - MSN
Finanzdaten der Recursion Pharmaceuticals Inc-Aktie (RXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):